ATE131056T1 - Verwendung von 2,3,4,5-tetrahydro-1h-3- benzazepinen bei der behandlung von neurologischen störungen. - Google Patents

Verwendung von 2,3,4,5-tetrahydro-1h-3- benzazepinen bei der behandlung von neurologischen störungen.

Info

Publication number
ATE131056T1
ATE131056T1 AT89112959T AT89112959T ATE131056T1 AT E131056 T1 ATE131056 T1 AT E131056T1 AT 89112959 T AT89112959 T AT 89112959T AT 89112959 T AT89112959 T AT 89112959T AT E131056 T1 ATE131056 T1 AT E131056T1
Authority
AT
Austria
Prior art keywords
benzazepines
tetrahydro
treatment
neurological disorders
chem
Prior art date
Application number
AT89112959T
Other languages
English (en)
Inventor
Joel G Berger
Wei K Chang
Elijah H Gold
John W Clader
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE131056T1 publication Critical patent/ATE131056T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT89112959T 1988-07-18 1989-07-14 Verwendung von 2,3,4,5-tetrahydro-1h-3- benzazepinen bei der behandlung von neurologischen störungen. ATE131056T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/223,739 US4973586A (en) 1986-01-16 1988-07-18 Fused benzazepines, compositions of, and medical use thereof

Publications (1)

Publication Number Publication Date
ATE131056T1 true ATE131056T1 (de) 1995-12-15

Family

ID=22837795

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89112959T ATE131056T1 (de) 1988-07-18 1989-07-14 Verwendung von 2,3,4,5-tetrahydro-1h-3- benzazepinen bei der behandlung von neurologischen störungen.

Country Status (13)

Country Link
US (1) US4973586A (de)
EP (2) EP0351733B1 (de)
JP (1) JPH0662420B2 (de)
KR (1) KR900701275A (de)
AT (1) ATE131056T1 (de)
AU (1) AU634973B2 (de)
CA (1) CA1336823C (de)
DE (1) DE68925004T2 (de)
DK (1) DK302190A (de)
ES (1) ES2080736T3 (de)
IL (1) IL90973A (de)
WO (1) WO1990000853A2 (de)
ZA (1) ZA895343B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5302716A (en) * 1986-01-16 1994-04-12 Schering Corporation Fused benzazepines
US5091526A (en) * 1988-07-29 1992-02-25 Schering Corporation Process for the enantiospecific synthesis of intermediates for hexahydro-benzo[d]-naphtho[2,1-b]azepines
CA2016465A1 (en) * 1989-06-02 1990-12-02 Zola Phillip Horovitz Method for preventing or treating anxiety employing a calcium channel blocker
WO1991011437A1 (en) * 1990-02-02 1991-08-08 Schering Corporation 4,5-cycloalkano-3-benzazepin-7-ol-derivatives and their use
US5312819A (en) * 1990-08-20 1994-05-17 Sandoz Ltd. Pharmaceutical compositions comprising clozapine and a radical scavenger
US5461147A (en) * 1993-09-27 1995-10-24 Schering Corporation Process for preparing benzazepine intermediates for the synthesis of D1 antagonists
US5463051A (en) * 1993-09-27 1995-10-31 Schering Corporation Process for preparing benzazepine intermediates for the synthesis of D1 antagonists
US5461148A (en) * 1993-09-27 1995-10-24 Schering Corporation Process for preparing benzazepine intermediates for the synthesis of D1 antagonists
US6517812B1 (en) * 1997-09-24 2003-02-11 The General Hospital Corporation Inhibition of psychostimulant-induced and nicotine-induced craving
US6410527B1 (en) 1998-03-02 2002-06-25 Schering Corporation Method of treating obsessive compulsive disorders, somatoform disorders, dissociative disorders, eating disorders, impulse control disorders, and autism
US6875866B2 (en) * 2002-02-21 2005-04-05 Schering Corporation Process for synthesis of D1 receptor antagonists
ES2308016T3 (es) * 2002-08-29 2008-12-01 Schering Corporation Anatagonistas selectivos de los receptores d1/d5 para el tratamiento de la obesidad y trastornos del snc.
EP1646623A2 (de) * 2003-05-22 2006-04-19 Schering Corporation 5-h-benzo[d]naphth[2,1-b]azepinderivate als selektive d1/d5-rezeptorantagonisten zur behandlung von obesitas und zns-erkrankungen
HUE058696T2 (hu) 2012-07-12 2022-09-28 Emalex Biosciences Inc Fúzionált benzazepinek a turett-szindróma terápiájában
PL3057595T3 (pl) 2013-10-18 2021-03-08 Emalex Biosciences, Inc. Skondensowane benzazepiny do leczenia jąkania

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3393192A (en) * 1965-04-26 1968-07-16 Schering Corp Novel benzazepines
GB1118688A (en) * 1967-02-17 1968-07-03 Scherico Ltd Novel benzazepines and process for making same
CH481110A (de) * 1967-02-17 1969-11-15 Geigy Ag J R Verfahren zur Herstellung von 1,2,4,5-Tetrahydro-3-azepinen
US3609138A (en) * 1967-12-22 1971-09-28 Ciba Geigy Corp 1-aryl-3-benzazepines
IL39381A0 (en) * 1971-05-10 1972-07-26 Sparamedica Ag Rheadan-type alkaloids,their preparation and pharmaceutical compositions containing them
US3983234A (en) * 1974-07-04 1976-09-28 Sandoz Ltd. Treatment of dyskinesias
US3939165A (en) * 1974-11-14 1976-02-17 Morton-Norwich Products, Inc. 5,6,6A,6B,7,8-Hexahydrobenz[a]phenanthridine hydrochloride
US4011319A (en) * 1975-07-02 1977-03-08 Smithkline Corporation Pharmaceutical compositions and methods involving benzazepine derivatives
US4284555A (en) * 1979-04-27 1981-08-18 Schering Corporation 7-Chloro-8(substituted amino carbonyloxy)-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines
US4315926A (en) * 1979-12-26 1982-02-16 Ciba-Geigy Corporation Dibenz[c,e]azepines
US4477378A (en) * 1980-02-05 1984-10-16 Schering Corp. Esters of substituted 8-hydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines
DE3007710C2 (de) * 1980-02-29 1982-04-15 Gödecke AG, 1000 Berlin 5,6;8,9-Tetrahydro-7H-dibenz(d,f)azonin-derivate, Verfahren zu deren Herstellung und Arzneimittel
EP0254737B1 (de) * 1986-01-16 1990-07-25 Schering Corporation Kondensierte benzazepine
DE3780649T2 (de) * 1987-07-15 1992-12-10 Schering Corp Kondensierte benzazepine.

Also Published As

Publication number Publication date
EP0351733A1 (de) 1990-01-24
ZA895343B (en) 1991-03-27
DK302190D0 (da) 1990-12-20
KR900701275A (ko) 1990-12-01
AU634973B2 (en) 1993-03-11
DE68925004D1 (de) 1996-01-18
ES2080736T3 (es) 1996-02-16
CA1336823C (en) 1995-08-29
DE68925004T2 (de) 1996-05-15
US4973586A (en) 1990-11-27
JPH0662420B2 (ja) 1994-08-17
EP0351733B1 (de) 1995-12-06
DK302190A (da) 1991-01-11
WO1990000853A8 (en) 2005-06-16
WO1990000853A2 (en) 1990-02-08
EP0434695A1 (de) 1991-07-03
IL90973A (en) 1994-04-12
AU3988489A (en) 1990-02-19
JPH03502100A (ja) 1991-05-16

Similar Documents

Publication Publication Date Title
DE68925004D1 (de) Verwendung von 2,3,4,5-Tetrahydro-1H-3-Benzazepinen bei der Behandlung von neurologischen Störungen.
ATE291011T1 (de) Hemmung der raf-kinase unter verwendung von symmetrisch und unsymmetrisch substituierten harnstoffen
ES2078440T3 (es) Compuestos farmaceuticos.
DK0636027T3 (da) Angiotensin-II-antogonister mod sygdomme forbundet med forringet neuronal ledningshastighed, især diabetisk neuropati
DE69431199D1 (de) Melatonin-Derivate zur Verwendung in der Behandlung von Schlafstörungen
ATE113591T1 (de) 4-benzyl-5-phenyl-2,4-dihydro-3h-1,2,4-triazol- - one und ihre verwendung als antikonvulsiva.
ES2044100T3 (es) Ciertas combinaciones de antagonistas del "paf" y antihistaminicos y metodos.
DE3751362D1 (de) 5-Aryl-3H-1,2,4-triazol-3-one und ihre Verwendung als Antikonvulsiva.
ATE116851T1 (de) 5-aryl-3h-1,2,4-triazol-3-one und ihre verwendung in der behandlung neurodegenerativer beschwerden.
ES2070934T3 (es) Derivados de oxotremorina 3- o 4-sustituidos.
DE69015411D1 (de) 5,11-Dihydro-6H-pyrido(2,3-b)(1,4)benzodiazepin-6-one und -thione und deren Verwendung bei der Vorbeugung und und Behandlung von AIDS.
DE69027577T2 (de) Verwendung von Benzothiazepinen zur Herstellung von Arzneimitteln zur Behandlung von epileptischen Anfällen
SE8802323L (sv) 8alfa-acylaminoergolin, dess framstaellning samt farmaceutiska kompositioner innehaallande detsamma
DE3884407D1 (de) Trifluormethyl-1-tetralinabkömmlinge, deren herstellung und verwendung bei der herstellung von verbindungen mit therapeutischer wirkung.
DE69001988T2 (de) Behandlung des schocks mit cyclodextrin und dessen derivaten.
DE68906028T2 (de) Verwendung von acetyl-d-carnitin zur therapeutischen behandlung von glaukom.
ATE79759T1 (de) Kombinationspraeparat zur behandlung von nervenzell-und nervenfasererkrankungen und verletzungen.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties